The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 48, Issue 7, 1999, Pages 935-941

  Nyholm, Birgit ^a   Ørskov, Lotte ^b   Hove, Karen Y ^b   Gravholt, Claus H ^b   Møller, Niels ^b   George, K ^b   Alberti, M M ^b   Moyses, Chris ^b   Kolterman, Orville ^b   Schmitz, Ole ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; FRUCTOSAMINE; GLUCAGON; INSULIN; PRAMLINTIDE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0041755815     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90232-9     Document Type: Article

References (41)

1. Mitsukawa T, Takemura J, Asai J, et al: Islet amyloid polypeptide response to glucose, insulin, and Somatostatin analogue administration. Diabetes 39:639-642, 1990
2. Kolterman OG, Gottlieb A, Moyses C, et al: Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC 137, a human amylin analogue. Diabetes Care 18:1179-1182, 1995
3. Thompson RG, Peterson J, Gottlieb A, et al: Effects of pramlintide, an analogue of human amylin, on plasma glucose profiles in patients with IDDM. Diabetes 46:632-636, 1997
4. Thompson RG, Pearson L, Kolterman OG: Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemic control in patients with IDDM: Effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia 40:1278-1285, 1997
5. Bretherton-Watt D, Gilby SG, Ghatei MA, et al: Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab 74:1032-1035, 1992
6. Wilding JPH, Khandan-Nia N, Bennet WM, et al: Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinemic euglycaemic clamp in humans. Diabetologia 37:166-169, 1994
7. Nyholm B, Møller N, Gravholt CH, et al: Acute effects of the human amylin analogue AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:1083-1089, 1996
8. Kong M-F, King P, Macdonald IA, et al: Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 40:82-88, 1997
9. Young AA, Gedulin BR, Rink TJ: Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 45:1-3, 1996
10. Gedulin BR, Young AA: Dose-response for glucagonostatic effects of amylin in rats. Metabolism 46:67-70, 1997
11. Leaming R, Johnson A, Hook G, et al: Amylin modulates insulin secretion in humans. Studies with an amylin antagonist. Diabetologia 38:A113, 1995 (abstr)
12. Unger RH: Glucagon physiology and pathophysiology. N Engl J Med 285:443-449, 1971
13. Lefèbvre PJ: Glucagon and its family revisited. Diabetes Care 18:715-730, 1995
14. Butler PC, Rizza RA: Contribution to postprandial hyperglycemia and effects on initial splanchnic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 40:73-81, 1991
15. Unger RH, Orei L: Hypothesis: The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1:14-16, 1975
16. Dobbs RE, Sakurai H, Sasaki H, et al: Glucagon: Role in the hyperglycemia of diabetes mellitus. Science 187:544-547, 1975
17. Ørskov H, Thomsen HG, Yde H: Wick-chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature 219:193-197, 1968
18. Harrison J, Hodson AV, Skillen AW, et al: Blood glucose, lactate, pyruvate, glycerol, 3-hydroxybutyrate and acetoacetate measurements in man using a centrifugal analyser with a fluorometric attachment. J Clin Chem Clin Biochem 26:141-146, 1988
19. 1c, glycated albumin and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 18:440-446, 1995
20. Kolterman OG, Schwartz S, Corder C, et al: Effects of 14 days' subcutaneous administration of the human amylin analogue pramlintide (AC137) on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 39:492-499, 1996
21. Jodka C, Green D, Young AA, et al: Amylin modulations of gastric emptying in rats depends upon intact vagus nerves. Diabetes 45:235A, 1996 (suppl 1, abstr)
22. Brown K, Menius A, Sandefer E, et al: The effects of amylin on changes in plasma glucose and gastric emptying following an oral glucose load in conscious dogs. Diabetes 43:172A, 1994 (suppl 1, abstr)
23. Young AA, Gedulin B, Vine W, et al: Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38:642-648, 1995
24. DeFronzo RA, Simonson D, Ferrannini E: Hepatic and peripheral insulin resistance: A common feature of type 2 and type 1 diabetes mellitus. Diabetologia 23:313-319, 1982
25. Pehling G, Tessari P, Gerich JE, et al: Abnormal meal carbohydrate disposition in insulin-dependent diabetes. J Clin Invest 74:985-991, 1984
26. Sherwin RS, Fisher M, Hendler R, et al: Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. N Engl J Med 294:455-461, 1976
27. Fineman M, Koda J, Kolterman O: Subcutaneous administration of a human amylin analogue suppresses postprandial glucagon concentrations in type 1 diabetic patients. Diabetes 47:A89, 1998 (abstr)
28. Rizza RA, Gerich JE: Persistent effect of sustained hyperglucagonemia on glucose production in man. J Clin Endocrinol Metab 48:352-355, 1979
29. Fradkin J, Samoon H, Feling P: Evidence for an important role of changes in, rather than absolute concentrations of, glucagon in the regulation of glucose production in humans. J Clin Endocrinol Metab 50:698-703, 1980
30. Ørskov L, Alberti KGMM, Mengel A, et al: Decreased hepatic glucagon responses in type I (insulin-dependent) diabetes mellitus. Diabetologia 34:521-526, 1991
31. Dineen S, Alzaid A, Turk D, et al: Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38:337-343, 1995
32. Silvestre RA, Peiro E, Degano P, et al: Inhibitory effects of rat amylin on the insulin response to glucose and arginine in the perfused rat pancreas. Regul Pept 31:23-31, 1990
33. Beumont K, Gedulin B, Jodka C, et al: Concentration-response for glucagonostatic effect of pramlintide in rats. Diabetologia 41:A168, 1998 (suppl 1, abstr)
34. Sexton PM. Paxinos G, Kenney MA, et al: In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62:553-567, 1994
35. Young AA: Role of amylin in nutrient intake - Animal studies. Diabet Med 14:S14-S18, 1997 (suppl 2)
36. Caro JF, Sinha MK, Kolaczynski JW, et al: Leptin: The tale of an obesity gene. Diabetes 45:1455-1462, 1996
37. Asplin CM, Hartog M, Goldie DJ, et al: Diurnal profiles of serum insulin, C-peptide and blood intermediary metabolites in insulin treated diabetics, their relationship to control of diabetes and the role of endogenous insulin secretion. Q J Med 190:343-360, 1979
38. Jensen MD, Heiling VJ, Miles JM: Effects of glucagon on free fatty acid metabolism in humans. J Clin Endocrinol Metab 72:308-315, 1991
39. Carlson MG, Snead WL, Cambell PJ: Regulation of free fatty acid metabolism by glucagon. J Clin Endocrinol Metab 77:11-15, 1993
40. Young AA, Wang MW, Cooper GJS: Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS Lett 291:101-104, 1991
41. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993